Pharmacotherapy considerations in advanced cardiac life support

Pharmacotherapy

Volumn 26, Issue 12 I, 2006, Pages 1703-1729

  Dager, William E ^a,b   Sanoski, Cynthia A ^c   Wiggins, Barbara S ^d   Tisdale, James E ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF THE SCIENCES   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e PURDUE UNIVERSITY   (United States)

Author keywords

ACLS; Advanced cardiac life support; Antiarrhythmic drugs; Cardiac arrest; Epinephrine; Pharmacist's role; Pharmacotherapy; Vasopressin

Indexed keywords

ADENOSINE; ADRENALIN; AMINOPHYLLINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CATECHOLAMINE DERIVATIVE; DIGOXIN ANTIBODY F(AB) FRAGMENT; DILTIAZEM; DIPYRIDAMOLE; DOPAMINE; ESMOLOL; FIBRINOLYTIC AGENT; GLUCAGON; IBUTILIDE; LIDOCAINE; MAGNESIUM; METOPROLOL; PROCAINAMIDE; PROPRANOLOL; UNINDEXED DRUG; VASOACTIVE AGENT; VASOPRESSIN; VERAPAMIL;

ANAPHYLAXIS; ASYSTOLE; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEFIBRILLATION; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG USE; DYSPNEA; ELECTROLYTE DISTURBANCE; EMERGENCY CARE; EMERGENCY HEALTH SERVICE; FLUSHING; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; INDUCED HYPOTHERMIA; LUNG EMBOLISM; OPTIMAL DRUG DOSE; PHARMACIST; PRACTICE GUIDELINE; PULSELESS VENTRICULAR TACHYCARDIA; QRS COMPLEX; QRS COMPLEX WIDENING; RECOMMENDED DRUG DOSE; RESUSCITATION; REVIEW; SIDE EFFECT; SINUS ARRHYTHMIA; SINUS PAUSE; SUDDEN DEATH; THORAX PAIN; TORSADE DES POINTES;

ADVANCED CARDIAC LIFE SUPPORT; DEATH, SUDDEN, CARDIAC; DRUG THERAPY; HEART ARREST; HUMANS; PHARMACISTS; PROFESSIONAL ROLE;

EID: 33845350627     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.12.1703     Document Type: Review

References (200)

1. Safar P. Ventilatory efficacy of mouth-to-mouth artificial respiration: airway obstruction during manual and mouth-to-mouth artificial respiration. JAMA 1958;167:335-41.
2. Jude JR, Kouwenhoven WB, Kinckerbocker GG. Cardiac arrest: a report of application of external cardiac massage on 118 patients. JAMA 1961;178:1063-70.
3. American Heart Association, International Liaison Committee on Resuscitation. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care: international consensus on science. Circulation 2000;102(suppl 8):I1-384.
4. National Academy of Sciences. Cardiopulmonary resuscitation. Statement by the ad hoc committee on cardiopulmonary resuscitation of the division of medical sciences, National Academy of Sciences, National Research Council. JAMA 1966;198:372-9.
5. Emergency Cardiovascular Care Committee, Subcommittees, and Task Forces of the American Heart Association. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2005;112(suppl 24):IV1-203.
6. Emergency Cardiovascular Care Committee, Subcommittees of the American Heart Association. Standards and guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiac care. JAMA 1992;268:2184-241.
7. Hachimi-Idrissi S, Huyghens L. Advanced cardiac life support update: the new ILCOR cardiovascular resuscitation guidelines. Eur J Emerg Med 2002;9:193-202.
8. Nolan JP, Deakin CD, Soar J, Bottiger BW, Smith G, for the European Resuscitation Council. European Resuscitation Council guidelines for resuscitation 2005. Section 4. Adult advanced life support. Resuscitation 2005;67(suppl 1):S39-86.
9. Eisenberg MS, Hallstrom AP Copass MK, Bergner L, Short F, Pierce J. Treatment of ventricular fibrillation: emergency medical technicians defibrillation and paramedic services. JAMA 1984;251:1723-6.
10. Eisenberg MS, Mengert TJ. Cardiac resuscitation. N Engl J Med 2001;344:1304-13.
11. Wenzel V, Krismer AC, Arntz R, Sitter H, Stadlbauer KH, Lindner KH, for the European Resuscitation Council Vasopressor during Cardiopulmonary Resuscitation Study Group. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 2004;350:105-13.
12. Xavier LC, Kern KB. Cardiopulmonary resuscitation guidelines 2000 update: what's happened since? Curr Opin Crit Care 2003;9:218-21.
13. The Public Access Defibrillation Trial Investigators. Public-access defibrillation and survival after out-of-hospital cardiac arrest. N Engl J Med 2004;315:637-46.
14. Bar Joseph G, Anbramson NS, Jansen-McWilliams L, et al. Clinical use of sodium bicarbonate during cardiopulmonary resuscitation: is it used sensibly? Resuscitation 2002;54:47-55.
15. Larsen MP, Eisenberg MS, Cummins RO, Hallstrom AP. Predicting survival from out-of-hospital cardiac arrest: a graphic model. Ann Emerg Med 1993;22:1652-8.
16. Weaver WD, Fahrencruch CE, Johnson DD, Hallstrom AP, Cobb LA, Compass MK. Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation. Circulation 1990;82:2027-34.
17. Montgomery WH, Brown DD, Hazinski MF, Clawson J, Newell LD, Flint L. Citizen response to cardiopulmonary emergencies. Ann Emerg Med 1993;22(2 pt 2):428-34.
18. Cox SV, Woodhouse SP, Weber M, Boyd P, Case C. Rhythm changes during resuscitation from ventricular fibrillation. Resuscitation 1993;26:53-61.
19. Herlitz J, Bang A, Ekstrom L, et al. A comparison between patients suffering in-hospital and out-of-hospital cardiac arrest in terms of treatment and outcome. J Int Med 2000;248:53-60.
20. Naeem N, Montenegro H. Beyond the intensive care unit: a review of interventions aimed at anticipating and preventing in-hospital cardiopulmonary arrest. Resuscitation 2005;67:13-23.
21. Gwinnutt CL, Columb M, Harris R. Outcome after cardiac arrest in adults in UK hospitals: effect of the 1997 guidelines. Resuscitation 2000;47:125-35.
22. Peberdy MA, Kaye W, Ornato JP, et al. Cardiopulmonary resuscitation in adults in the hospital: a report of 14,720 cardiac arrests from the National Registry of Cardiopulmonary Resuscitation. Resuscitation 2003;58:297-308.
23. Epstein AE, Powell J, Yao Q, et al. In-hospital versus out-of-hospital presentation of life-threatening ventricular arrhythmias predicts survival. J Am Coll Cardiol 1999;34:1111-16.
24. Nolan JP, de Latorre FJ, Steen PA, Chamberlain DA, Bossaert LL. Advanced life support drugs: do they really work? Curr Opin Crit Care 2002;8:212-18.
25. Zhong JQ, Dorian P. Epinephrine and vasopressin during cardiopulmonary resuscitation. Resuscitation 2005;66:263-9.
26. Tang W, Weil MH, Sun S, Nox M, Yang L, Gazmuri RJ. Epinephrine increases the severity of postresuscitation myocardial dysfunction. Circulation 1995;92:3089-93.
27. Mulligan KA, McKnite SH, Lindner KH, Lindstrom PJ, Detloff B, Lurie KG. Synergistic effects of vasopressin plus epinephrine during cardiopulmonary resuscitation. Resuscitation 1997;35:265-71.
28. Otto CW, Yakaitis RW, Blitt CD. Mechanism of action of epinephrine in resuscitation from asphyxiai arrest. Crit Care Med 1981;9:321-4.
29. Herlitz J, Ekstrom L, Wennerblom B, et al. Lidocaine in out-of-hospital ventricular fibrillation: does it improve survival? Resuscitation 1997;33:199-205.
30. Vandycke C, Martens P. High doses versus standard dose epinephrine in cardiac arrest: a meta-analysis. Resuscitation 2000;45:161-6.
31. Berg RA, Otto CW, Kern KB, et al. High-dose epinephrine results in greater mortality after resuscitation from prolonged cardiac arrest in pigs: a prospective, randomized study. Crit Care Med 1994;22:282-90.
32. Van Walraven C, Stiell IG, Wells GA, Hebert PC, Vandemheen K. Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest? Ann Emerg Med 1998;32:544-53.
33. Wang HE, Min A, Hostler D, Change CC, Callaway CW. Differential effects of out-of-hospital interventions on short-and long-term survival after cardiopulmonary arrest. Resuscitation 2005;67:69-74.
34. Hebert P, Weitzman BN, Steill IG, Stark RM. Epinephrine in cardiopulmonary resuscitation. J Emerg Med 1991;9:487-95.
35. Koscove EM, Pardis NA. Successful resuscitation from cardiac arrest using high-dose epinephrine therapy. JAMA 1988;259:3031-4.
36. Sherman BW, Munger MA, Foulke GE, Rutherford WF, Panacek EA. High-dose versus standard-dose epinephrine treatment of cardiac arrest after failure of standard therapy. Pharmacotherapy 1997;17:242-7.
37. Stiell IG, Wells GA, Field BJ, et al. Improved out-of-hospital cardiac arrest survival through the inexpensive optimization of an existing defibrillation program: OPALS study phase II. Ontario prehospital advanced life support. JAMA 1999;281:1175-81.
38. Paradis NA, Martin GB, Rivers EP, et al. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. JAMA 1990;263:1106-13.
39. Lindner KH, Ahnefeld FW, Prengel AW. Comparison of standard and high-dose adrenaline in the resuscitation of asystole and electromechanical dissociation. Acta Anaesthesiol Scand 1991;35:253-6.
40. Brown CG, Martin DR, Pepe PE, et al, for the Multicenter High-Dose Epinephrine Study Group. A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital. N Engl J Med 1992;327:1051-5.
41. Callaham M, Madsen CS, Barton CW, Saunders CE, Pointer J. A randomized clinical trial of high-dose epinephrine and norepinephrine vs standard-dose epinephrine in prehospital cardiac arrest. JAMA 1992;268:2667-72.
42. Steill IG, Herbert PC, Weitzman BN, et al. High-dose epinephrine in adult cardiac arrest. N Engl J Med 1992;327:1045-50.
43. Woodhouse SP, Cox S, Boyd P, Case C, Weber M. High dose and standard dose adrenaline do not alter survival compared with placebo in cardiac arrest. Resuscitation 1995;30:243-9.
44. Thrush DN, Downs JB, Smith RA. Is epinephrine contraindicated during cardiopulmonary resuscitation? Circulation 1997;96:2709-14.
45. Behringer W, Kittler H, Sterz F, et al. Cumulative epinephrine dose during cardiopulmonary resuscitation and neurologic outcome. Ann Intern Med 1998;129:450-6.
46. Gueugniaud PY, Mols P, Goldstein P, et al. A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital. N Engl J Med 1998;339:1595-601.
47. Choux C, Gueugniaud PY, Barbieux A, et al. Standard dose versus repeated high dose of epinephrine in cardiac arrest outside the hospital. Resuscitation 1995;29:3-9.
48. Johansson J, Hammerby R, Oldgren J, Rubertsson S, Gedeborg R. Adrenaline administration during cardiopulmonary resuscitation: poor adherence to clinical guidelines. Acta Anaesthesiol Scand 2004;48:909-13.
49. Manisterski Y, Vaknin Z, Ben-Abraham R, et al. Endotracheal epinephrine: a call for larger doses. Anesth Analg 2002;95:1037-41.
50. Crespo SG, Schoffstall JM, Fuhs LR, Spivey WH. Comparison of two doses of endotracheal epinephrine in a cardiac arrest model. Ann Emerg Med 1991;20:230-4.
51. Nieman JT, Stratton SJ. Endotracheal versus intravenous epinephrine and atropine in out-of-hospital "primary" and postcountershock asystole. Crit Care Med 2000;28:1815-19.
52. Mayr VD, Wenzel V, Voelckel WG, et al. Developing a vasopressor combination in a pig model of adult asphyxiai cardiac arrest. Circulation 2001;104:1651-6.
53. Morris DC, Dereczyk BE, Grzybowski M, et al. Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation. Acad Emerg Med 1997;4:878-83.
54. Lindner KH, Strohmenger HU, Ensinger H, Hetzel WD, Ahnefeld FW, Georgieff M. Stress hormone response during and after cardiopulmonary resuscitation. Anesthesiology 1992;77:662-8.
55. Lindner KH, Prengel AW, Brinkmann A, Strohmenger HU, Lindner IM, Lurie KG. Vasopressin administration in refractory cardiac arrest. Ann Intern Med 1996;124:1061-4.
56. Lindner KH, Dirks B, Strohmenger HU, Prengel AW, Lindner IM, Lurie KG. A randomized comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997;349:535-7.
57. Stiell IG, Hebert PC, Wells GA, et al. Vasopressin versus epinephrine for inhospital cardiac arrest: a randomized controlled trial. Lancet 2001;358:105-9.
58. Wenzel V, Arntz HR, Lindner KH. Vasopressin versus epinephrine for cardiopulmonary resuscitation [letter]. N Engl J Med 2004;350:2208.
59. Krismer AC, Wenzel V, Stadibauer KH, et al. Vasopressin during cardiopulmonary resuscitation: a progress report. Crit Care Med 2004;32(suppl 9):S432-5.
60. Efrati O, Barak A, Ben-Abraham R, et al. Should vasopressin replace adrenaline for endotracheal drug administration? Crit Care Med 2003;31:572-6.
61. Wenzel V, Lindner KH. Arginine vasopressin during cardiopulmonary resuscitation: laboratory evidence, clinical experience and recommendations, and a view to the future. Crit Care Med 2002;30(suppl):S157-61.
62. Shehab AMA, Kendall MJ. Cardiac arrest: a role for vasopressin. J Clin Pharm Ther 2004;29:299-306.
63. Guyette FX, Guimond GE, Hostler D, Callaway CW. Vasopressin administered with epinephrine is associated with a return of a pulse in out-of-hospital cardiac arrest. Resuscitation 2004;63:277-82.
64. Kodama I, Kamiya K, Toyama J. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 1999;84:R20-8.
65. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999;341:871-8.
66. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2002;346:884-90.
67. Rea RS, Kane-Gill SL, Rudis MI, et al. Comparing intravenous amiodarone or lidocaine, or both, outcomes for inpatients with pulseless ventricular arrhythmias. Crit Care Med 2006;34:1617-23.
68. Skrifvars MB, Kuisma M, Boyd J, et al. The use of undiluted amiodarone in the management of out-of-hospital cardiac arrest. Acta Anaesthesiol Scand 2004;48:582-7.
69. Taylor MD, Van Dyke K, Bowman LL, et al. A characterization of amiodarone-induced pulmonary toxicity in F344 rats and identification of surfactant protein-D as a potential biomarker for the development of the toxicity. Toxicol Appl Pharmacol 2000;167:182-90.
70. Reinhart PG, Lai YL, Gairola CG. Amiodarone-induced pulmonary fibrosis in Fischer 344 rats. Toxicology 1996;110:95-101.
71. Grundler WG, Weil MH, Raclow EC. Pharmacology of cardiopulmonary resuscitation. Acute Care 1984;10:2-32.
72. Singh BN. Initial antiarrhythmic drug therapy during resuscitation from sudden death: a time for a fundamental change in strategy? J Cardiovasc Pharmacol Therapeut 2000;5:3-9.
73. Fatovich DM, Prentice DA, Dobb GJ. Magnesium in cardiac arrest (the MAGIC trial). Resuscitation 1997;35:237-41.
74. Cannon LA, Heiselman DE, Dougherty JM, Jones J. Magnesium levels in cardiac arrest victims: relationship between magnesium levels and successful resuscitation. Ann Emerg Med 1987;16:1195-9.
75. Noc M, Stajer D, Horvat M. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol 1990;65:679-80.
76. Peuhkurinen K, Niemela M, Ylitalo A, Linnaluoto M, Lilja M, Juvonen J. Effectiveness of amiodarone as a single oral dose for recent onset atrial fibrillation. Am J Cardiol 2000;85:462-5.
77. Watt AH, Routledge PA. Transient bradycardia and subsequent sinus tachycardia produced by intravenous adenosine in healthy adult subjects. Br J Clin Pharmacol 1986;21:533-6.
78. Chang M, Wrenn K. Adenosine dose should be less when administered through a central line. J Emerg Med 2002;22:195-8.
79. Mclntosh-Yellin NL, Drew BJ, Scheinman MM. Safety and efficacy of central intravenous bolus administration of adenosine for termination of supraventricular tachycardia. J Am Coll Cardiol 1993;22:741-5.
80. Watt AH, Bernard MS, Webster J, Passani SL, Stephens MR, Routledge PA. Intravenous adenosine in the treatment of supraventricular tachycardia: a dose ranging study and interaction with dipyridamole. Br J Clin Pharmacol 1986;21:227-30.
81. Tisdale JE. Arrhythmias. In: Tisdale JE, Miller DA, ed. Drug-induced diseases: prevention, detection and management. Bethesda, MD: American Society of Health-System Pharmacists, 2005:289-327.
82. Mader TJ, Smithline HA, Durkin L, Scriver G. A randomized controlled trial of intravenous aminophylline for atropine-resistant out-of-hospital asystolic cardiac arrest. Acad Emerg Med 2003;10:192-7.
83. Dimarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The adenosine for PSVT study group. Ann Intern Med 1990;113:104-10.
84. Hood MA, Smith WM. Adenosine versus verapamil in the treatment of supraventricular tachycardia: a randomized double-crossover trial. Am Heart J 1992;123:1543-9.
85. Belhassen B, Viskin S. What is the drug of choice for the termination of paroxysmal supraventricular tachycardia: verapamil, adenosine triphosphate, or adenosine? Pacing Clin Electrophysiol 1993;16:1735-41.
86. Wittwer LK, Muhr MD. Adenosine for the treatment of PSVT in the prehospital arena: efficacy of an initial 6 mg dosing regimen. Prehospital Disaster Med 1997;12:237-9.
87. Parker RB, McCollam PL. Adenosine in the episodic treatment of paroxysmal supraventricular tachycardia. Clin Pharm 1990;9:261-71.
88. Griffith MJ, Linker NJ, Ward DE, Camm AJ. Adenosine in the diagnosis of broad complex tachycardia. Lancet 1988;1:672-5.
89. Goldstein RE, Boccuzi SJ, Cruess D, Nattel S, for the Adverse Experience Committee and the Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991;83:52-60.
90. Phillips BG, Gandhi AJ, Sanoski CA, Just VL, Bauman JL. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter. Pharmacotherapy 1997;17:1238-45.
91. Slavik RS, Tisdale JE, Borzak S. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. Prog Cardiovasc Dis 2001;44:121-52.
92. Pharmacia. Corvert (ibutilide fumarate) package insert. Kalamazoo, MI; 2002
93. Levine JH, Massumi A, Scheinman MM, et al, for the Intravenous Amiodarone Multicenter Trial Group. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. J Am Coll Cardiol 1996;27:67-75.
94. Kowey PR, Levine JH, Herre JM, et al, for the Intravenous Amiodarone Multicenter Investigators Group. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. Circulation 1995;92:3255-63.
95. Scheinman MM, Levine JH, Cannom DS,, et al, for the Intravenous Amiodarone Multicenter Investigators Group. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation 1995;92:3264-72.
96. Halperin BD, Kron J, Cutler JE, Kudenchuk PJ, McAnulty JH. Misdiagnosing ventricular tachycardia in patients with underlying conduction disease and similar sinus and tachycardia morphologies. West J Med 1990;152:677-82.
97. Steill IG, Wells GA, Herbert PC, Laupacis A, Weitzman BN. Association of drug therapy with survival in cardiac arrest: limited role of advanced cardiac life support drugs. Acad Emerg Med 1995;2:264-73.
98. Hallstrom AP, Cobb LA, Yu BH, Weaver WD, Fahrenbruch CE. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970-1985. Am J Cardiol 1991;68:1025-31.
99. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 1988;77:392-7.
100. Allegra J, Lavery R, Cody R, et al. Magnesium sulfate in the treatment of refractory ventricular fibrillation in the prehospital setting. Resuscitation 2001;49:245-9.
101. Thel MC, Armstrong AL, McNulty SE, et al. Randomized trial of magnesium in in-hospital cardiac arrest. Lancet 1997;350:1272-6.
102. Coon GA, Clinton JE, Ruiz E. Use of atropine for bradyasystolic prehospital cardiac arrest. Ann Emerg Med 1981;10:462-7.
103. Altun A, Kirdar C, Ozbay G. Effect of aminophylline in patients with atropine-resistant late advanced atrioventricular block during acute inferior myocardial infarction. Clin Cardiol 1998;21:759-62.
104. Hatton J, Cohen JL. Electrolytes - potassium. In: Baumgartner T, ed. Guide to parenteral micronutrition, 2nd ed. Chicago: Lympomed, 1991.
105. Aufderheide TP, Martin DR, Oison DW, et al. Prehospital bicarbonate use in cardiac arrest: a 3-year experience. Am J Emerg Med 1992;10:4-7.
106. Roberts D, Landolfo K, Light RB, Dobson K. Early predictors of mortality for hospitalized patients suffering cardiopulmonary arrest. Chest 1990;97:413-19.
107. Weil MH, Ruiz CE, Michaels S, et al. Acid-base determinants of survival after cardiopulmonary resuscitation. Crit Care Med 1985;13:888-92.
108. Kette F, Weil MH, Gazmuri RJ. Buffer solutions may compromise cardiac resuscitation by reducing coronary perfusion pressure. JAMA 1991;266:2121-6.
109. Kette F, Weil MH, von Planta M, Gazmuri RJ, Rackow EC. Buffer agents do not reverse intramyocardial acidosis during cardiac arrest. Circulation 1990;81:1660-6.
110. Jaffe AS. New and old paradoxes: acidosis and cardiopulmonary resuscitation. Circulation 1989;80:1079-82.
111. National Academy of Sciences, National Research Council. Standards and guidelines for cardiopulmonary resuscitation and emergency cardiac care. JAMA 1986;255:2905-14. (Erratum in JAMA 1986;256:1727.)
112. Dembo DH. Calcium in advanced life support. Crit Care Med 1981;9:358-9.
113. Stempien A, Katz AM, Messineo FC. Calcium and cardiac arrest. Ann Intern Med 1986;105:603-6.
114. Stueven HA, Thompson BM, Aprahamian C, Tonsfeldt DJ. Calcium chloride: reassessment of use in asystole. Ann Emerg Med 1984;13:820-2.
115. Stueven HA, Thompson BM, Aprahamian C, Darin JC. Use of calcium in prehospital arrest. Ann Emerg Med 1983;12:136-9.
116. Lindner KH, Ahnefeld FW, Bowder IM. Comparison of different doses of epinephrine on myocardial perfusion and resuscitation success during cardiopulmonary resuscitation in a pig model. Am J Emerg Med 1991;9:27-31.
117. Cao L, Weil MH, Sun S, Tang W. Vasopressor agent for cardiopulmonary resuscitation. J Cardiovasc Pharm 2003;8:115-21.
118. Brown CG, Birinyi F, Werman HA, Davis EA, Hamlin RL. The comparative effects of epinephrine versus phenylephrine on cerebral blood flow during cardiopulmonary resuscitation. Resuscitation 1986;14:171-83.
119. Dunser MW, Mayr AJ, Ulmer H, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Anal 2001;93:7-13.
120. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-82.
121. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73.
122. Obritsch MD, Bestul DJ, Jung R, Fish DN, MacLaren R. The role of vasopressin in vasodilatory septic shock. Pharmacotherapy 2004;24:1050-63.
123. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the international cooperative pulmonary embolism registry (ICOPER). Lancet 1999;353:1386-9.
124. Wood KE. The presence of shock defines the threshold to initiated thrombolytic therapy in patients with pulmonary embolism. Intensive Care Med 2002;28:1537-46.
125. Ruiz-Bailén M, Cuadra JAR, de Hoyos EA. Thrombolysis during cardiopulmonary resuscitation in fulminant pulmonary embolism: a review. Crit Care Med 2001;29:2211-19.
126. Büller HR, Agnelli G, Hall RD, Hyers TM, Prins MH, Roskob GE. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:S401-28.
127. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 2004;110:e82-292.
128. Menon V, Harrington RA, Hochman JS, et al. Thrombolysis and adjunctive therapy in acute myocardial infarction: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(suppl):S549-75.
129. Tsikouris JP, Tsikouris AP. A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction. Pharmacotherapy 2001;21:207-17.
130. Browse NL, James DCO. Streptokinase and pulmonary embolism. Lancet 1964;2:1039-43.
131. Anonymous. Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study. JAMA 1970;214:2163-72.
132. Anonymous. Urokinase-streptokinase embolism trial. Phase 2 results: a cooperative study. JAMA 1974;229:1606-13.
133. The PIOPED Investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism: a collaborative study by the PIOPED investigators. Chest 1990;97:528-33.
134. Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase combined with heparin versus heparin alone in massive pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol 1992;20:520-6.
135. Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990;98:1473-9.
136. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomized trial assessing right ventricular function and pulmonary perfusion. Lancet 1993;341:507-11.
137. Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis 1995;2:227-9.
138. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W, for the Management Strategies and Prognosis of Pulmonary Emoblism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143-50.
139. Hyers TM, Stengle JM, Sherry S. Treatment of pulmonary embolism with urokinase: results of clinical trial (phase 1). Circulation 1970;42:979-80.
140. Spōhr F, Böttiger BW. Safety of thrombolysis during cardiopulmonary resuscitation. Drug Saf 2003;26:367-79.
141. Dalen JE, Alpert JS, Hirsh J. Thrombolytic therapy for pulmonary embolism: Is it effective? Is it safe? When is it indicated? Arch Intern Med 1997;157:2550-6.
142. Dong B, Jirong Y, Liu G, Wang Q, Wu T. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev 2006;(2):CD004437.
143. Goldhaber SZ. Thrombolysis in pulmonary embolism: a debatable indication. Thromb Haemos 2001;86:444-51.
144. Murray JL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997;349:1269-76.
145. Williams GR, Jiang JG, Matchar DB, Samsa GP. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke 1999;30:2523-8.
146. Genetech, Inc. Activase (alteplase, recombinant) prescribing information. South San Francisco, CA; 2002.
147. The National Institute of Neurological Disorders, Stroke t-PA Study Group. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA stroke trial. Stroke 1997;28:2119-25.
148. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European cooperative acute stroke study (ECASS). JAMA 1995;274:1017-25.
149. The National Institute of Neurological Disorders, Stroke rt-PA Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
150. Hacke W, Kaste M, Fieschi C, et al, Second European-Australasian Acute Stroke Study Investigators. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-51.
151. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study - a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 1999;282:2019-26.
152. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999;340:1781-7.
153. Marier JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NlNDS rt-PA stroke study. Neurology 2000;55:1649-55.
154. American Heart Association, the International Liaison Committee on Resuscitation (ILCOR). Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care: an international consensus on science. Circulation 2000;102(suppl 8):I204-16.
155. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:S483-512.
156. Mahr NC, Valdes A, Lamas G. Use of glucagon for acute intravenous diltiazem toxicity. Am J Cardiol 1997;79:1570-1.
157. Papadapoulos J, O'Neill MG. Utilization of a glucagon infusion in the management of a massive nifedipine overdose. J Emerg Med 2000;18:453-5.
158. Levey GS, Epstein SE. Activation of adenyl cyclase by glucagon in cat and human heart. Circ Res 1969;24:151-6.
159. Entman ML, Levey GS, Epstein SE. Mechanism of action of epinephrine and glucagon on the heart: evidence of a cyclic 3′,5′-AMP mediated increase in cardiac sarcotubular calcium stores. Circ Res 1969;25:429-38.
160. Illingworth RN. Glucagon for β-blocker poisoning. Practitioner 1979;223:683-5.
161. Salzberg MR, Gallagher EJ. Propranolol overdose. Ann Emerg Med 1980;9:26-7.
162. Shore ET, Cepin D, Davidson MJ. Metoprolol overdose. Ann Emerg Med 1981;10:524-7.
163. Peterson CD, Leeder JS, Sterner S. Glucagon therapy for β-blocker overdose. Drug Intell Clin Pharm 1984;18:394-8.
164. Weinstein RS, Cole S, Knaster HB, Dahlbert T. β-Blocker overdose with propranolol and with atenolol. Ann Emerg Med 1985;14:161-3.
165. DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and β-blocker toxicity. Toxicol Rev 2004;23:223-38.
166. Parmley WW, Glick G, Sonnenblick EH. Cardiovascular effects of glucagon in man. N Engl J Med 1968;279:12-17.
167. Pollack CV. Utility of glucagon in the emergency department. J Emerg Med 1993;11:195-205.
168. Ramoska EA, Spiller HA, Winter M, Borys D. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. Ann Emerg Med 1993;22:196-200.
169. Hofer CA, Smith JK, Tenholder MF. Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options. Am J Med 1993;95:431-8.
170. Brimacombe JR, Scully M, Swainston R. Propranolol overdose: a dramatic response to calcium chloride. Med J Aust 1991;155:267-8.
171. Pertoldi F, D'Orlando L, Mercante WP. Electromechanical dissociation 48 hours after atenolol overdose: usefulness of calcium chloride. Ann Emerg Med 1998;31:777-81.
172. Kerns W II, Kline J, Ford MD. β-Blocker and calcium channel blocker toxicity. Emerg Med Clin North Am 1994;12:365-90.
173. Lip GYH, Ferner RE. Poisoning with anti-hypertensive drugs: β-adrenoceptor blocker drugs. J Hum Hypertens 1995;9:213-21.
174. Allen NM, Dunham GD. Treatment of digitalis intoxication with emphasis on the clinical use of digoxin immune Fab. DICP 1990;24:991-8.
175. Antman EM, Wenger TL, Butler VP, Haber E, Smith TW. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific F(ab) antibody fragments: final report of a multicenter study. Circulation 1990;81:1744-52.
176. Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune F(ab) therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol 1991;17:590-8.
177. Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet 1995;28:483-93.
178. Oddo M, Schaller MD, Feihl F, Ribordy V, Liaudet L. From evidence to clinical practice: effective implementation of therapeutic hypothermia to improve patient outcome after cardiac arrest. Crit Care Med 2006;34:1865-73.
179. Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002;346:549-56. (Erratum in N Engl J Med 2002;346:1756.)
180. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;346:557-63.
181. Nordmark J, Rubertsson S. Induction of mild hypothermia with infusion of cold (4°C) fluid during ongoing experimental CPR. Resuscitation 2005;66:357-65.
182. Kim F, Olsufka M, Carlbom D, et al. Pilot study of rapid infusion of 2 L of 4°C normal saline for induction of mild hypothermia in hospitalized, comatose survivors of out-of-hospital cardiac arrest. Circulation 2005;112:715-19.
183. Del Guercio LR. Clinical management of a patient in shock: shock and pulmonary embolism. Clin Anesth 1965;2:167-81.
184. Sun SJ, Weil MH, Tang W, Povoas HP, Mason E. Combined effects of buffer and adrenergic agents on postresuscitation myocardial function. J Pharmacol Exp Ther 1999;291:773-7.
185. Talit U, Braun S, Halkin H, Shargorodsky B, Laniado S. Pharmacokinetic differences between peripheral and central drug administration during cardiopulmonary resuscitation. J Am Coll Cardiol 1985;6:1073-7.
186. Prete MR, Hannan CJ, Burke FM. Plasma atropine concentrations via intravenous, endotracheal, and imraosseous administration. Am J Emerg Med 1987;5:101-4.
187. Miller B, Craddock L, Hoffenberg S, et al. Pilot study of intravenous magnesium sulfate in refractory cardiac arrest: safety data and recommendations for future studies. Resuscitation 1995;30:3-14.
188. Doan LA. Peripheral versus central venous delivery of medications during CPR. Ann Emerg Med 1984;13:37-9.
189. Jasani MS, Nadkarni VM, Finkelstein MS, Mandell GA, Salzman SK, Norman ME. Effects of different techniques of endotracheal epinephrine administration in pediatric porcine hypoxic-hypercarbic cardiopulmonary arrest. Crit Care Med 1994;22:1174-80.
190. Naganobu K, Hasbe Y, Uchiyama Y, Hagio M, Ogawa H. A comparison of distilled water and normal saline as diluents for endobronchial administration of epinephrine in the dog. Anesth Analg 2000;91:317-21.
191. 2 with endobronchial administration: dilution with normal saline or distilled water? Ann Emerg Med 1990;19:1314-17.
192. Neimann JT, Stratton SJ, Cruz B, Lewis RJ. Endotracheal drug administration during out-of-hospital resuscitation: where are the survivors? Resuscitation 2002;53:153-7.
193. Quinten DN, O'Byrne G, Aitkenhead AR. Comparison of endotracheal and peripheral intravenous adrenaline in cardiac arrest: is the endotracheal route reliable? Lancet 1987;1:828-9.
194. Dager W. Achieving optimal antiarrhythmic therapy in advanced cardiac life support. Crit Care Med 2006;34:1825-6.
195. Miller WA, Kernaghan SG. CRP: should the pharmacist get involved? Hospitals 1974;48:79-84.
196. Raehl CL, Bond CA. 1998 National clinical pharmacy services study. Pharmacotherapy 2000;20:436-60.
197. Machado C, Barlows BG, Marsh WA, et al. Pharmacists on the emergency cardiopulmonary resuscitation team: their responsibilities, training, and attitudes. Hosp Pharm 2003;38:40-9.
198. Ludwig DJ, Abramowitz PW. The pharmacist as a member of the CPR team: evaluation by other health professionals. Drug Intel Clin Pharm 1983;17:463-5.
199. Bond CA, Raehl CL, Franke T. Clinical pharmacy services and hospital mortality rates. Pharmacotherapy 1999;19:556-64.
200. Dager W. Inventory control for advanced cardiac life support medications. Ann Pharmacother 2002;36:942-3.